HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC
PHASE1Not yet recruitingINTERVENTIONAL
Enrollment
40
Participants
Timeline
Start Date
December 1, 2024
Primary Completion Date
December 1, 2026
Study Completion Date
December 1, 2027
Conditions
NSCLC Stage IV
Interventions
DRUG
HY1272
Each patient will receive HY1272 weely or HY1272 weely+Oshitinib 80mg P.O. daily
All Listed Sponsors
lead
Newsoara Biopharma Co., Ltd.
INDUSTRY
NCT06218940 - HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC | Biotech Hunter | Biotech Hunter